Conversely, the degradation of NLRP3 is relieved due to the decreased expression of VANGL2 in IBD, resulting in excessive activation of the NLRP3 inflammasome and promoting the release of IL-1β, ultimately accelerating the progression of IBD. Here, VANGL2 is linked to inflammatory bowel disease.